Loading
Total declarations
Companies
▲ Purchases (9 ops.)
▼ Sales (0 ops.)
Latest filing published 27 May 2026 for Assembly Biosciences, INC., €10.7M. Read the official filing
Filing timeline
BuySaleGilead Sciences, Inc.
Insider track record
Disclosed buys
9
Disclosed sells
0
Signal history
Closed purchases
Market purchases
9
Positive at T+90
0%
Median T+90
-12.2%
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +70.3%Entry US$11.07 · Close at T+365 US$18.85
- -18.6%Entry US$15.85 · Close at T+365 US$12.90
- -25.1%Entry US$20.44 · Close at T+365 US$15.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Gilead Sciences, Inc.: trading record in brief
Gilead Sciences, Inc. is a declared insider at 5 companies; the most frequent names are Assembly Biosciences, Inc., Arcus Biosciences, Inc. and Xilio Therapeutics, Inc. We count 11 filings; the first trade dates from 27 June 2023 and the latest from 26 May 2026.
The open-market record is one-sided, with 9 purchases worth €358.8M and not one sale. The amount is not disclosed for 2 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 1 share grant.
A typical purchase (the median) is worth €14.3M. Of 9 purchases, 1 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Ninety days after publication, 3 purchases show a median change of -12.2%, with the price up in 0% of them. These figures describe past trades and do not predict future prices.
The record was last updated on 27 May 2026 with a share grant (€10.7M) in Assembly Biosciences, Inc. The most recent open-market purchase was published on 3 October 2025, 380 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Gilead Sciences, Inc.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations11 total
471,698 shares@ US$26.502.36% mcap35.6% of flowCommon StockSEC:0001123292-26-000751:0
2,295,920 sharesCommon StockSEC:0001123292-25-000510:0
Canonical exit: 6 Nov 2025 (T+90)
1,363,636 shares@ US$11.004.4% of flowCommon StockSEC:0001062993-25-003084:0
Canonical exit: 19 May 2025 (T+90)
940,499 shares@ US$21.3764.4% of flowCommon StockSEC:0000904454-24-000669:0
Canonical exit: 19 Mar 2025 (T+90)
1,759,978 shares@ US$1.0483.6% of flowCommon StockSEC:0001062993-24-020910:0
Canonical exit: 18 Mar 2025 (T+90)
179,500 sharesCommon StockSEC:0000904454-24-000391:0
Canonical exit: 15 Sept 2024 (T+90)
485,250 shares@ US$0.7616.4% of flowCommon StockSEC:0001062993-24-008004:0
Canonical exit: 1 Jul 2024 (T+90)
3,216,119 sharesCommon StockSEC:0001062993-24-003026:0
15,238,095 shares@ US$21.0090.2% of flowCommon StockSEC:0001104659-24-008868:0
Canonical exit: 28 Apr 2024 (T+90)
1,010,000 shares@ US$19.265.4% of flowCommon StockSEC:0001104659-23-077015:0
Canonical exit: 26 Sept 2023 (T+90)
2,930,870 shares@ US$3.75100.0% of flowCommon StockSEC:0001062993-23-014111:0
Canonical exit: 25 Sept 2023 (T+90)
11 of 11 declarations
